-+ 0.00%
-+ 0.00%
-+ 0.00%

ZIPALERTINIB PLUS CHEMOTHERAPY DEMONSTRATES 6-MONTH MEDIAN PROGRESSION-FREE SURVIVAL BENEFIT IN REZILIENT3 PHASE 3 TRIAL IN FIRST-LINE EGFR EXON 20 INSERTION MUTATION NON-SMALL CELL LUNG CANCER

Reuters·09/13/2026 23:15:02

Please log in to view news